Recurrence of any episodes at one year (active suicidal behavior) · bipolar disorder
It is very uncertain whether lamotrigine changes recurrence of any episodes at one year (active suicidal behavior) compared with lithium (very low certainty).
1 finding from 1 review
Treatment withdrawal · bipolar disorder
1 finding from 1 review
Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long term) · bipolar disorder
Lamotrigine showed no clear difference in withdrawal from treatment due to any reason, 6‐12 months after… compared with lithium (moderate certainty).
1 finding from 1 review
Any reported adverse effects up to 12 weeks after starting treatment (short term) · bipolar disorder
1 finding from 1 review
Any reported adverse effects 6‐12 months after initiating the intervention (long term) · bipolar disorder
Lamotrigine probably leads to lower any reported adverse effects 6‐12 months after initiating the… compared with lithium (moderate certainty).
1 finding from 1 review
Recurrence of manic episode at one year · bipolar disorder
Lamotrigine probably leads to higher recurrence of manic episode at one year compared with lithium (moderate certainty).
1 finding from 1 review
Recurrence of depressive episode at one year · bipolar disorder
Lamotrigine showed no clear difference in recurrence of depressive episode at one year compared with lithium (moderate certainty).
1 finding from 1 review
Health status and quality of life · bipolar disorder
1 finding from 1 review
Total severity score from depression and mania symptom scores, such as HDRS and the YMRS · bipolar disorder
1 finding from 1 review
Response rate at 3 weeks (primary efficacy outcome) · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in response rate at 3 weeks (primary efficacy outcome) compared with lithium (moderate certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in number of participants with any adverse event at 2‐4 weeks (primary… compared with lithium (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3 weeks (secondary… compared with lithium (low certainty).
1 finding from 1 review
Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania
1 finding from 1 review
Dropout · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in dropout rate ‐ All‐cause At 2‐4 weeks (secondary acceptability… compared with lithium (moderate certainty).
1 finding from 1 review
Response rate at 8 weeks (primary efficacy outcome) · Children and adolescents with acute mania
It is very uncertain whether valproate changes response rate at 8 weeks (primary efficacy outcome) compared with lithium (very low certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · Children and adolescents with acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: somnolence/sedation · Children and adolescents with acute mania
It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 8 weeks (secondary… compared with lithium (very low certainty).
1 finding from 1 review
Change in symptom severity of mania rating scale at 8 weeks (secondary efficacy outcome) · Children and adolescents with acute mania
1 finding from 1 review
Dropout · Children and adolescents with acute mania
It is very uncertain whether valproate changes dropout rate ‐ All‐cause At 8 weeks (secondary acceptability outcome) compared with lithium (very low certainty).
1 finding from 1 review